Allergy Relief 2014
The March/April 2014 Allergy Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Children’s Claritin Chewable, Children’s Allegra Allergy meltable tablets, Children’s Benadryl Allergy Liquid, Nasacort Allergy 24HR, Mucinex Allergy, Hyland’s 4 Kids Complete Allergy and Similasan Kids Allergy Eye Relief.
Study: POC testing for infectious diseases could spell opportunity for community pharmacy
NEW YORK — Recent research suggests that point-of-care testing for infectious diseases in community pharmacies could not only benefit patients but could also represent an opportunity for pharmacy as they look to strengthen their foothold along the front lines of health care.
The research, titled “Point-of-care testing for infectious diseases: Opportunities, barriers, and considerations in community pharmacy,” was published in the Journal of American Pharmacists Association.
According to researchers, “POC testing for infectious diseases could benefit patients and society, and represents an opportunity to expand pharmacy services in community pharmacies. Existing barriers to the implementation of such services in community pharmacies, including deficits in pharmacist training and education, along with state regulatory and legislative variance and vagueness in statutes governing pharmacy, are not insurmountable.”
Actavis, Valeant announce FDA approval for Metronidazole gel
DUBLIN and LAVAL, Quebec — Actavis and Valeant Pharmaceuticals International announced that the Food and Drug Administration approved the new drug application for Metronidazole 1.3% vaginal gel.
The antibiotic is used for the treatment of bacterial vaginosis, an infection caused by an imbalance in the normal bacteria of vagina. It’s the most common vaginal infection in women ages 15 years to 44 years. Metronidazole 1.3% provides a single-dose treatment that is packaged in a pre-filled disposable applicator.
"The approval of Metronidazole 1.3% is a significant milestone for Actavis and provides an important new option with a single-dose treatment for women suffering from BV," said Fred Wilkinson, president of Actavis Global R&D. "The expected launch of the product later this year will establish a promising long-term opportunity for Actavis and support the continued growth of our industry-leading Women’s Health franchise."
Actavis acquired the rights to Metronidazole 1.3% from Valeant Pharmaceuticals International in April 2013. Under the terms of the agreement, Actavis will acquire the rights to the drug for up to $57 million in upfront payments, milestone payments and certain guaranteed royalty payments during the first three years of commercialization, the companies said. The bacterial vaginosis market in the United States is valued at approximately $140 million annually, according to IMS Health.